Free tool
FAERS Monitor: Fosamax
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020560 or its brand name (Fosamax, Alendronate Sodium). Reports on generic versions are filed under their own applications.
Reports
83,679
Serious
66,990
80% of reports
Hospitalization
32,348
Death reported
10,774
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pain13,040
- fatigue12,258
- drug ineffective11,759
- femur fracture11,065
- arthralgia10,508
- rheumatoid arthritis10,154
- alopecia9,989
- abdominal discomfort9,939
- systemic lupus erythematosus9,388
- pemphigus9,118
- rash8,790
- glossodynia8,478
- arthropathy8,299
- swelling7,864
- hypertension7,697
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 3,094 |
| 2005 | 3,438 |
| 2006 | 3,302 |
| 2007 | 3,751 |
| 2008 | 3,254 |
| 2009 | 3,260 |
| 2010 | 4,088 |
| 2011 | 4,620 |
| 2012 | 8,031 |
| 2013 | 3,906 |
| 2014 | 2,882 |
| 2015 | 2,893 |
| 2016 | 2,519 |
| 2017 | 2,434 |
| 2018 | 2,492 |
| 2019 | 2,771 |
| 2020 | 3,385 |
| 2021 | 4,878 |
| 2022 | 4,270 |
| 2023 | 2,985 |
| 2024 | 4,689 |
| 2025 | 4,240 |
| 2026 | 2,496 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,970,480 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pemphigusSignal | 9,118 | 672.9 | 647.2 | 1,660,785 |
| glossodyniaSignal | 8,478 | 152.5 | 148.6 | 794,096 |
| femur fractureSignal | 11,065 | 139.1 | 136.0 | 976,969 |
| systemic lupus erythematosusSignal | 9,388 | 90.0 | 88.0 | 608,887 |
| arthropathySignal | 8,299 | 43.9 | 43.0 | 296,969 |
| rheumatoid arthritisSignal | 10,154 | 24.6 | 24.1 | 210,357 |
| swellingSignal | 7,864 | 23.0 | 22.5 | 151,994 |
| abdominal discomfortSignal | 9,939 | 15.8 | 15.5 | 130,344 |
| alopeciaSignal | 9,989 | 13.4 | 13.2 | 109,960 |
| hypertensionSignal | 7,697 | 9.4 | 9.2 | 56,542 |
| arthralgiaSignal | 10,508 | 6.5 | 6.4 | 48,532 |
| painSignal | 13,040 | 5.4 | 5.3 | 47,509 |
| rashSignal | 8,790 | 5.2 | 5.1 | 29,427 |
| fatigueSignal | 12,258 | 4.0 | 3.9 | 28,242 |
| drug ineffectiveSignal | 11,759 | 2.3 | 2.2 | 8,671 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.